KRAS and familial pancreatic carcinoma: A previous study reported a similar phenomenon in which KRAS inhibition led to a dramatic upregulation of ribosomal proteins L26 and L29 (RPL26 and RPL29), while knockdown of RPL26 or RPL29 expression significantly suppressed cell proliferation of pancreatic cancer, suggesting that upregulation of RPL26 or RPL29 might counteract the effect of KRAS silencing in pancreatic cancer cells [33].